TNF and interstitial lung disease: Patients with ILD were more likely to receive non-TNF inhibitors than JAKis (OR 0.21, CI 0.06–0.72), but the reverse was true for patients with diabetes mellitus (OR 5.00, CI 1.24–20.22).